Currently, the newest research reports that NKG2A is a new checkpoint, and blocking NKG2A with monalizumab could promote the antitumour immune activity of CD8+ T cells and NK cells, which could be used as a supplement to the first generation of cancer immunotherapy (11). The gene discussed is KLRC1; the disease is cancer.